Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Next Previous
Trial Profile

A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hafnium oxide (Primary) ; Nivolumab; Pembrolizumab
  • Indications Bladder cancer; Cancer metastases; Cervical cancer; Gastric cancer; Head and neck cancer; Liver cancer; Liver metastases; Lung cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Skin cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Nanobiotix

Most Recent Events

  • 24 Oct 2025 Planned End Date changed from 30 May 2028 to 30 Aug 2027.
  • 24 Oct 2025 Status changed from recruiting to active, no longer recruiting.
  • 29 Sep 2025 According to a Nanobiotix media release, updated data from cohorts 1 and 2 of Study presented as a "Top-rated Abstract in Head and Neck Cancer" at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on September 29th.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top